- Home
- KLRS vs CULP Comparison
KLRS vs CULP Comparison
Compare KLRS & CULP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- CULP
- Stock Information
- Founded
- KLRS 2019
- CULP 1972
- Country
- KLRS United States
- CULP United States
- Employees
- KLRS N/A
- CULP N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- CULP Textiles
- Sector
- KLRS Health Care
- CULP Consumer Discretionary
- Exchange
- KLRS Nasdaq
- CULP Nasdaq
- Market Cap
- KLRS 46.0M
- CULP 52.7M
- IPO Year
- KLRS N/A
- CULP N/A
- Fundamental
- Price
- KLRS $4.78
- CULP $3.79
- Analyst Decision
- KLRS Strong Buy
- CULP
- Analyst Count
- KLRS 3
- CULP 0
- Target Price
- KLRS $21.50
- CULP N/A
- AVG Volume (30 Days)
- KLRS 107.9K
- CULP 17.0K
- Earning Date
- KLRS 11-13-2025
- CULP 12-03-2025
- Dividend Yield
- KLRS N/A
- CULP N/A
- EPS Growth
- KLRS N/A
- CULP N/A
- EPS
- KLRS N/A
- CULP N/A
- Revenue
- KLRS N/A
- CULP $207,391,000.00
- Revenue This Year
- KLRS N/A
- CULP $1.93
- Revenue Next Year
- KLRS N/A
- CULP $2.77
- P/E Ratio
- KLRS N/A
- CULP N/A
- Revenue Growth
- KLRS N/A
- CULP N/A
- 52 Week Low
- KLRS $2.14
- CULP $3.42
- 52 Week High
- KLRS $23.69
- CULP $5.94
- Technical
- Relative Strength Index (RSI)
- KLRS 47.17
- CULP 27.16
- Support Level
- KLRS $4.67
- CULP $3.95
- Resistance Level
- KLRS $5.10
- CULP $4.05
- Average True Range (ATR)
- KLRS 0.41
- CULP 0.12
- MACD
- KLRS -0.03
- CULP -0.04
- Stochastic Oscillator
- KLRS 39.41
- CULP 4.49
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.